An interventional study of Pregabalin and venlafaxine concomitant therapy and Esketamine plus pregabalin and venlafaxine concomitant therapy in Fibromyalgia, Pregabalin and Esketamine, sponsored by Beijing Tiantan Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Fibromyalgia with a site in China — 14 open to participants now, 14 under way, none of them phase 3. Fibromyalgia · China.
Among the 29 studies in Fibromyalgia with a site in China, this one is the 15th largest by enrollment of the 23 interventional ones that give a count, is one of 10 that started in 2025, is one of 19 with no phase, and was the 23rd registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →14 of the 29 studies in Fibromyalgia with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 120 across the 23 interventional studies, 344 across the 6 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 29 have an industry lead sponsor. The 10 most frequent:
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
Beijing Tiantan Hospital has 9 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
7 of the studies in Fibromyalgia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07157852Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia | 2027-06-30 |
| NCT07196657Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia | 2027-06-30 |
| NCT07230197Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 29 studies in Fibromyalgia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fibromyalgia is a chronic pain syndrome where current medications have limited efficacy and a slow onset of action. Esketamine shows potential as a rapid-acting analgesic, but previous low-dose studies failed to demonstrate long-term benefits. The efficacy of higher-dose ESK as an adjunctive therapy when standard treatments are insufficient remains unclear.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregabalin and venlafaxine concomitant therapy
Drug: Pregabalin and venlafaxine concomitant therapy
Esketamine plus pregabalin and venlafaxine concomitant therapy
Drug: Esketamine plus pregabalin and venlafaxine concomitant therapy
The control group will only receive an increased dosage of pregabalin and venlafaxine regimen. Each participant will be instructed with the same dose escalation regimen, until they reach the maximal tolerated dose (MTD) or the ceiling dose or the maximum daily recommended dose. The maximum recommended daily dose of pregabalin was 450 mg and venlafaxine was 225 mg.
The treatment group, in addition to the increased pregabalin and venlafaxine medication dosage regimen, will also receive a single intravenous infusion of esketamine on the day of enrollment. Plasma concentrations of esketamine and its metabolites will be measured at the end of infusion to enable a limited characterization of systemic exposure and to support exploratory exposure-response analyses. Each participant will be instructed with the same dose escalation regimen, until they reach the maximal tolerated dose (MTD) or the ceiling dose or the maximum daily recommended dose. The maximum recommended daily dose of pregabalin was 450 mg and venlafaxine was 225 mg.
Change from baseline in the mean pain intensity
This outcome is calculated as the average of daily 24-hour pain intensity scores recorded in patient diaries over 7 consecutive days using NRS.
Time frame: At the week 1.
Average pain intensity
The pain intensity will be measured based on NRS, where 0 represents no pain and 10 represents worst pain imaginable.
Time frame: At the weeks 1, 2, 4, 8, and 12
Proportion of patients achieving pain reduction at 50%;
The proportion of patients achieving a ≥ 50% reduction in mean baseline pain intensity. The pain intensity will be measured based on NRS, where 0 represents no pain and 10 represents worst pain imaginable.
Time frame: at weeks 1, 2, 4, 8, and 12
The median pain relief time
The median pain relief time, defined as the time of 50% decrease in NRS score from baseline. Pain intensity will be measured using the NRS, where 0 indicates no pain, and 10 represents the worst imaginable pain.
Time frame: Through study completion, an average of 12 weeks
The Revised FM Impact Questionnaire (FIQR)
The FIQR is used to assessed health status and functional disablity. FIQR is a 21-item self-administered questionnaire, based on symptoms reported within the preceding 7 days. FIQR total score ranges from 0 to 100, with higher values indicating worse health status.
Time frame: At the weeks 4, 8, and 12
Hospital Anxiety and Depression scale (HADS)
The HADS is used to assess anxiety (7 items) and depression (7 items). Scores range from 0 to 21 on each subscale, with higher scores indicating worse symptomatology.
Time frame: At the weeks 4, 8, and 12
The short-form 36 Health Survey (SF-36)
The SF-36 assesses health-related quality of life, capturing preferences across various health states. It assesses 8 dimensions: physical functioning, physical role limitations due to physical health, bodily pain, general health, vitality, social functioning, emotional role limitations due to emotional problems, and mental health. Scores range from 0 to 100 for each dimension, with higher scores indicating better health status.
Time frame: At the weeks 4, 8, and 12
Multidimensional Fatigue Inventory (MFI)
Fatigue is evaluated using the MFI, a 20-item assessment tool with five domains. Higher scores indicate a higher degree of fatigue.
Time frame: At the weeks 4, 8, and 12
Medical Outcomes Study Sleep Scale (MOS)
The MOS is a questionnaire comprising 12 items that assess various aspects of sleep using a 6-point ordinal scale (1 indicating permanence and 6 indicating absence).
Time frame: At the weeks 4, 8, and 12
The doses of pregabalin and venlafaxine
Time frame: at weeks 1, 2, 4, 8, and 12
Adverse events
Time frame: Through study completion, an average of 12 weeks
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures and appendices) are available. Derived data supporting the findings of this study are available from the corresponding author Fang Luo on request.
Ran from Sep 2025 to primary completion in Jun 2026, 8 months.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 8 months is below that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jun 2027 → Jun 2026 and completion Aug 2027 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.